ACP Journal Club. Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes.
作者信息
Aron David C, Pogach Leonard M
机构信息
Cleveland VA Medical Center, Cleveland, Ohio, USA.
出版信息
Ann Intern Med. 2010 Nov 16;153(10):JC5-9. doi: 10.7326/0003-4819-153-10-201011160-02009.
Abstract
摘要
相似文献
1
ACP Journal Club. Intensive glucose control did not reduce a composite of microvascular events more than standard control in type 2 diabetes.《美国内科医师学会杂志俱乐部》。在2型糖尿病中，强化血糖控制在减少微血管事件综合指标方面并不比标准控制更有效。
Ann Intern Med. 2010 Nov 16;153(10):JC5-9. doi: 10.7326/0003-4819-153-10-201011160-02009.
2
ACP Journal Club. Intensive BP control and/or glucose control did not reduce microvascular events in hypertensive type 2 diabetes.《美国医师协会杂志俱乐部》。强化血压控制和/或血糖控制并未降低高血压2型糖尿病患者的微血管事件发生率。
Ann Intern Med. 2012 Oct 16;157(8):JC4-7. doi: 10.7326/0003-4819-157-8-201210160-02007.
3
ACP journal club. Intensive glucose control increased mortality and did not prevent CV events compared with standard glucose control in type 2 diabetes.《美国内科医师学会杂志俱乐部》。与2型糖尿病的标准血糖控制相比，强化血糖控制增加了死亡率且未能预防心血管事件。
Ann Intern Med. 2011 May 17;154(10):JC5-02. doi: 10.7326/0003-4819-154-10-201105170-02002.
4
ACP Journal Club. Intensive and standard glucose control did not differ for major CV events or death in poorly controlled type 2 diabetes.《美国内科医师学会杂志俱乐部》。在控制不佳的2型糖尿病患者中，强化血糖控制与标准血糖控制在主要心血管事件或死亡方面并无差异。
Ann Intern Med. 2009 Mar 17;150(6):JC3-8. doi: 10.7326/0003-4819-150-6-200903170-02008.
5
ACP Journal Club. Review: Intensive glucose control reduced some CV events but did not change mortality in type 2 diabetes.《美国内科医师学会杂志俱乐部》。综述：强化血糖控制可减少部分心血管事件，但未改变2型糖尿病患者的死亡率。
Ann Intern Med. 2009 Sep 15;151(6):JC3-6. doi: 10.7326/0003-4819-151-6-200909150-02006.
6
ACP Journal Club. Review: Intensive glucose lowering does not reduce mortality in type 2 diabetes.《美国内科医师学会杂志俱乐部》。综述：强化降糖不能降低2型糖尿病患者的死亡率。
Ann Intern Med. 2011 Dec 20;155(12):JC6-4. doi: 10.7326/0003-4819-155-12-201112200-02004.
7
ACP Journal Club. Review: intensive glucose control reduces surrogate, but not clinical, renal outcomes in type 2 diabetes.《美国内科医师学会杂志俱乐部》述评：强化血糖控制可降低2型糖尿病患者的替代指标性肾脏结局，但不能降低临床肾脏结局。
Ann Intern Med. 2012 Nov 20;157(10):JC5-6. doi: 10.7326/0003-4819-157-10-201211200-02006.
8
ACP Journal Club. Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes.《美国内科医师学会杂志俱乐部》。在2型糖尿病中，将二甲双胍添加到胰岛素治疗中并不能改善微血管和大血管疾病的综合情况。
Ann Intern Med. 2009 Jul 21;151(2):JC1-12. doi: 10.7326/0003-4819-151-2-200907210-02012.
9
ACP Journal Club. Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors.《美国内科医师学会杂志俱乐部》。那格列奈未能降低糖耐量受损且有心血管危险因素患者的糖尿病发生率或心血管事件发生率。
Ann Intern Med. 2010 Jun 15;152(12):JC6-10. doi: 10.7326/0003-4819-152-12-201006150-02010.
10
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.2 型糖尿病/空腹血糖受损患者的血压目标：来自传统和贝叶斯随机效应荟萃分析的观察结果。
Circulation. 2011 Jun 21;123(24):2799-810, 9 p following 810. doi: 10.1161/CIRCULATIONAHA.110.016337. Epub 2011 May 31.
Zotero 插件